×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PDSB – pds biotechnology corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PDSB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/15
01:21 pm
pdsb
PDS Biotechnology (PDSB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $15.00 price target on the stock.
Medium
Report
PDS Biotechnology (PDSB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $15.00 price target on the stock.
4/15
08:45 am
pdsb
PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial
High
Report
PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial
4/4
01:04 am
pdsb
PDS Biotechnology (PDSB) was upgraded by Wall Street Zen from "sell"
High
Report
PDS Biotechnology (PDSB) was upgraded by Wall Street Zen from "sell"
3/30
09:11 pm
pdsb
PDS Biotechnology Corp (PDSB) Q4 2025 Earnings Call Highlights: Financial Discipline Amid ... [Yahoo! Finance]
Medium
Report
PDS Biotechnology Corp (PDSB) Q4 2025 Earnings Call Highlights: Financial Discipline Amid ... [Yahoo! Finance]
3/30
07:15 am
pdsb
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement [Yahoo! Finance]
Medium
Report
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement [Yahoo! Finance]
3/30
07:00 am
pdsb
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement
Medium
Report
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement
3/29
05:39 pm
pdsb
PDS Biotechnology FY 2025 Earnings Preview [Seeking Alpha]
High
Report
PDS Biotechnology FY 2025 Earnings Preview [Seeking Alpha]
3/24
04:05 pm
pdsb
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results
Medium
Report
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results
Date
Time
Symbol
Company Name
Action
%Chg
3/30/2026
07:00 am
PDSB
pds biotechnology corporation
MISS
Report
-6.5%
pds biotechnology corporation
11/13/2025
07:30 am
PDSB
pds biotechnology corporation
BEAT
Report
-11.3%
pds biotechnology corporation
8/13/2025
07:00 am
PDSB
pds biotechnology corporation
BEAT
Report
-6.5%
pds biotechnology corporation
5/14/2025
07:30 am
PDSB
pds biotechnology corporation
BEAT
Report
-2.2%
pds biotechnology corporation
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/15
08:55 am
pdsb
Form 8-K PDS Biotechnology Corp For: Apr 15
High
Report
Form 8-K PDS Biotechnology Corp For: Apr 15
3/30
05:43 pm
pdsb
Form 10-K PDS Biotechnology Corp For: Dec 31
High
Report
Form 10-K PDS Biotechnology Corp For: Dec 31
3/30
07:06 am
pdsb
Form 8-K PDS Biotechnology Corp For: Mar 30
Medium
Report
Form 8-K PDS Biotechnology Corp For: Mar 30
3/3
06:48 pm
pdsb
Form 4 PDS Biotechnology Corp For: Jan 12 Filed by: Freitag Gregory Gene
High
Report
Form 4 PDS Biotechnology Corp For: Jan 12 Filed by: Freitag Gregory Gene
3/3
06:48 pm
pdsb
Form 4 PDS Biotechnology Corp For: Jan 12 Filed by: Brown Spencer D.
High
Report
Form 4 PDS Biotechnology Corp For: Jan 12 Filed by: Brown Spencer D.
3/3
06:48 pm
pdsb
Form 4 PDS Biotechnology Corp For: Jan 12 Filed by: Boesgaard Lars
High
Report
Form 4 PDS Biotechnology Corp For: Jan 12 Filed by: Boesgaard Lars
3/3
06:48 pm
pdsb
Form 4 PDS Biotechnology Corp For: Jan 12 Filed by: BEDU-ADDO FRANK
High
Report
Form 4 PDS Biotechnology Corp For: Jan 12 Filed by: BEDU-ADDO FRANK
3/3
06:48 pm
pdsb
Form 4 PDS Biotechnology Corp For: Jan 12 Filed by: CONN GREGORY
High
Report
Form 4 PDS Biotechnology Corp For: Jan 12 Filed by: CONN GREGORY
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/14
Q1/2019 3/31/2019 EPS 1.470 ZacksConsensus N/A ActVsEst N/A - N/A
41.4%
10/3 PDS Biotechnology Corp. Announces Clinical Collaboration with Merck 31.3%
2/5 PDS Biotechnology to Present at the 2020 BIO CEO & Investor Conference 16.3%
7/30 Form 8-K PDS Biotechnology Corp For: Jul 29 11.8%
10/22 PDS Biotechnology Completes Manufacturing of Clinical Batches of PDS0101 10.7%
11/25 PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019 7.5%
12/3 PDS Biotechnology to Present at the 12th Annual LD Micro Main Event 6.7%
3/2 Form SC 13D PDS Biotechnology Corp Filed by: NETSCIENTIFIC PLC 6.6%
9/19 PDS Biotechnology Reports Clinical Data for Its Novel Immunotherapy PDS0101 in Follow up to Phase 1 Human Trial 6.1%
12/23 PDS Biotechnology Corporation (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $10.00 price target on the stock. 5.4%
10/3 PDS Biotechnology Corp. Announces Clinical Collaboration with Merck 31.3%
2/5 PDS Biotechnology to Present at the 2020 BIO CEO & Investor Conference 16.3%
7/30 Form 8-K PDS Biotechnology Corp For: Jul 29 11.8%
10/22 PDS Biotechnology Completes Manufacturing of Clinical Batches of PDS0101 10.7%
11/25 PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019 7.5%
12/3 PDS Biotechnology to Present at the 12th Annual LD Micro Main Event 6.7%
3/2 Form SC 13D PDS Biotechnology Corp Filed by: NETSCIENTIFIC PLC 6.6%
9/19 PDS Biotechnology Reports Clinical Data for Its Novel Immunotherapy PDS0101 in Follow up to Phase 1 Human Trial 6.1%
12/23 PDS Biotechnology Corporation (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $10.00 price target on the stock. 5.4%
TOP News Decliners
2/11
PDS Biotechnology Corporation Announces Pricing of Public Offering of Approximately $12 Million of Shares of Common Stock
-25.8%
9/24 Form 8-K PDS Biotechnology Corp For: Sep 24 -15.4%
12/17 Form S-1 PDS Biotechnology Corp -14.9%
3/9 PDS Biotechnology Corporation (NASDAQ: PDSB) is now covered by analysts at Noble Financial. They set an "outperform" rating and a $5.45 price target on the stock. -14.2%
12/13 Form 8-K PDS Biotechnology Corp For: Dec 11 -13.5%
2/11 Form FWP PDS Biotechnology Corp Filed by: PDS Biotechnology Corp -12.7%
11/14 Form S-8 PDS Biotechnology Corp -12.7%
4/16 PDS Biotechnology Initiates Novel Vaccine Development Programs For COVID-19 and Universal Influenza; Delay of PDS0101 VERSATILE-002 trial -9.8%
11/25 Form 8-K PDS Biotechnology Corp For: Nov 25 -8.8%
6/4 Form S-8 PDS Biotechnology Corp -8.4%
9/24 Form 8-K PDS Biotechnology Corp For: Sep 24 -15.4%
12/17 Form S-1 PDS Biotechnology Corp -14.9%
3/9 PDS Biotechnology Corporation (NASDAQ: PDSB) is now covered by analysts at Noble Financial. They set an "outperform" rating and a $5.45 price target on the stock. -14.2%
12/13 Form 8-K PDS Biotechnology Corp For: Dec 11 -13.5%
2/11 Form FWP PDS Biotechnology Corp Filed by: PDS Biotechnology Corp -12.7%
11/14 Form S-8 PDS Biotechnology Corp -12.7%
4/16 PDS Biotechnology Initiates Novel Vaccine Development Programs For COVID-19 and Universal Influenza; Delay of PDS0101 VERSATILE-002 trial -9.8%
11/25 Form 8-K PDS Biotechnology Corp For: Nov 25 -8.8%
6/4 Form S-8 PDS Biotechnology Corp -8.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: